Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)

INTRODUCTION: The optimal treatment for extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae bloodstream infections has yet to be defined. Retrospective studies have shown conflicting results, with most data suggesting the non-inferiority of beta-lactam–beta-lactamase inhibitor combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bitterman, Roni, Koppel, Fidi, Mussini, Cristina, Geffen, Yuval, Chowers, Michal, Rahav, Galia, Nesher, Lior, Ben-Ami, Ronen, Turjeman, Adi, Huberman Samuel, Maayan, Cheng, Matthew P, Lee, Todd C, Leibovici, Leonard, Yahav, Dafna, Paul, Mical
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871690/
https://www.ncbi.nlm.nih.gov/pubmed/33558347
http://dx.doi.org/10.1136/bmjopen-2020-040210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871690/
https://www.ncbi.nlm.nih.gov/pubmed/33558347
http://dx.doi.org/10.1136/bmjopen-2020-040210

Ejemplares similares